Pliant Therapeutics, Inc. (PLRX)

Market Cap	898.11M
Revenue (ttm)	5.03M
Net Income (ttm)	-144.42M
Shares Out	59.83M
EPS (ttm)	-2.74
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	523,628
Open	15.97
Previous Close	15.94
Day's Range	14.98 - 15.99
52-Week Range	14.98 - 36.64
Beta	1.25
Analysts	Strong Buy
Price Target	48.36 (+222.19%)
Earnings Date	Nov 7, 2023

About PLRX

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase IIa trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. It also develops PLN-1474, a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated wit...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 3, 2020
• Employees: 155
• Stock Exchange: NASDAQ
• Ticker Symbol: PLRX

Financial Performance

In 2022, PLRX's revenue was $9.69 million, an increase of 27.91% compared to the previous year's $7.57 million. Losses were -$123.32 million, 26.8% more than in 2021.

Analyst Forecast

According to 11 analysts, the average rating for PLRX stock is "Strong Buy." The 12-month stock price forecast is $48.36, which is an increase of 222.19% from the latest price.

Price Target

$48.36

(222.19% upside)

Analyst Consensus: Strong Buy